Neuromyelitis Optica (NMO) Treatment
Neuromyelitis Optica (NMO) Treatment
Treatment in this condition is two jobs rather than three, and the reason to separate them at the outset is that each is regularly presented as though it were the other. The first is treating the attack that is happening now , which is a matter of hours: high-dose corticosteroid, and plasma exchange added early rather than kept in reserve, because in this condition the attack is where the disability is made. The second is preventing the next one , which is continuous maintenance immunosuppression taken by people who often feel entirely well — and which is not an adjunct to the treatment but the treatment. A third job sits alongside both and is the one most often left to a person to arrange alone: spasticity, neuropathic pain, bladder function, fatigue and vision, which are where a day's cost actually sits. This page sets out all three, and names the thing that has to be said before any of them: several of the medicines used for multiple sclerosis make this condition worse .
Treating the attack that is happening
An attack in this condition is not a relapse that will probably get better on its own. It is the event that determines what a person can do for the rest of their life, and the treatment window is measured in hours rather than days. Two interventions carry most of it.
High-dose intravenous corticosteroid. Started as soon as the attack is recognised rather than after the imaging is reported, and given for a defined course. What it does is damp the inflammation at the lesion. What it requires while it is being given is attention to blood sugar, blood pressure, sleep and mood, and gastric protection where that is warranted. What it does not do is prevent the next attack, which is a separate drug and a separate decision.
Plasma exchange. The antibody and complement are in the circulation, and removing them is a mechanical way to stop what is happening. The point that changes outcomes is the timing: it is used early in the severe attack rather than after steroids have failed. Keeping it in reserve until day ten is keeping it for the attack after the one that matters. It is a procedure with its own requirements — venous access, a course of sessions rather than one, and a setting that can run it — and those are worth knowing about before they are needed rather than during.
Three other things belong in the same window and are not treatment in the usual sense. A urinary infection is looked for and treated, because infection is both the commonest trigger of a pseudo-attack and the commonest reason an attack is worse than it needed to be. The deficit is written down and measured — how far a person can walk, what the vision is in each eye, whether the bladder empties — so that recovery is a measurement rather than an impression. And the question of why now is asked: was there an infection, has treatment been stopped or changed, is this the first attack or the fifth. That answer changes what is discussed afterwards rather than only what happens this week.
What should not happen is the reverse: a severe attack watched for a few days to see whether it resolves, or a mild one treated with steroids because steroids are available. Both are decisions about the person in front of the clinician, and in this condition the first one is the more expensive of the two.
Preventing the next one
If there is one sentence to take from this guide, it is this one: because disability in this condition is made of attacks rather than of something accumulating between them, preventing the next attack is the treatment. It is not a second-line consideration, not something added after a second event, and not optional in someone who currently feels well.
What maintenance immunosuppression does is reduce the frequency and severity of attacks. What the agents have in common is that they suppress the immune response that is producing the antibody; what they differ in is how they do it, what monitoring they require, and what they commit a person to. Several approaches exist, including conventional steroid-sparing immunosuppression used for many years, B-cell-directed therapy, and agents targeting the complement pathway or the interleukin-6 receptor. Which one is right is a conversation rather than a ranking, and the inputs to it are set out in the next section.
What a person takes on alongside the medicine is the part most often under-described. Each agent has its own monitoring: blood tests at defined intervals, surveillance for particular infection risks, and — for some — vaccination given before immunosuppression begins rather than after. What should be said about availability is said at the outset: where a medicine recommended is not carried out within this pathway, that is named before any payment is discussed, not at the end of a workup.
Two sentences close this section. The first: the treatment is taken by people who feel entirely well, for a disease whose next event may never come — which is the difficult part of it and the reason the decision deserves to be explained rather than issued. The second: stopping it without a plan is the commonest route into an attack that did not need to happen, and the rebound activity reported after several agents are stopped is the reason the change is planned rather than taken.
How the choice is actually made
It is not made by ranking medicines against each other, and it is worth saying why: the comparison that matters is not between two drugs but between a drug and a person's circumstances. What follows is what is actually weighed.
| Item | What it decides |
|---|---|
| What the disease has done so far | How much weight the efficacy side of the balance carries. A first attack that recovered fully is a different conversation from a third one that did not |
| Monitoring, and whether it is liveable | How often blood tests are needed, how often imaging is needed, and whether that is compatible with where the person lives and works |
| Risks, stated one at a time | Infection risk most of all, and the specific surveillance that some agents carry. Stated as individual risks rather than as a category |
| Route and frequency | Tablet, injection or infusion, and how often — which is a decision about a life rather than about pharmacology |
| Pregnancy and contraception | Whether the medicine can be continued through conception and pregnancy, whether it needs a washout, and what the plan is for the postpartum months |
| Vaccination | Which vaccines are needed before starting, and which are not safe once immunosuppressed — which is why the conversation happens before the prescription |
| What is already there | Other conditions, other medicines, and the interactions that make one risk more or less acceptable than another |
The medicine that was right at thirty-five may not be right at forty-five with a different scan, a different job, or a different plan for children. The interval at which it is reviewed is part of the prescription, and so is the question of what would prompt a change — a new attack, a change on imaging, an adverse effect, or a change in circumstances. Any medicine recommended that is not given within this pathway is named at the outset, before any payment is discussed.
Treating the symptoms rather than the disease
This is the job that most affects a day, and the one most often left to a person to arrange alone. None of what follows prevents the next attack. All of it changes what a day costs, and most of it is available. The point of setting it out as a list is that each item should be asked about at a review by name.
| Symptom | What is done | What it does not do |
|---|---|---|
| Spasticity and spasms | Stretching and positioning first, then medicines for tone; focal treatment where one muscle group is the problem | Not a sign the disease is active. Some tone is useful for standing and transferring, and removing all of it can remove that |
| Neuropathic pain | Medicines for nerve pain rather than for nociceptive pain, and the band-like pain around the trunk specifically | Not managed with anti-inflammatory analgesia, and not something to endure because the scan is unchanged |
| Bladder | Assessment of whether it fails to store or fails to empty, which are opposite problems with opposite treatments; treating infection promptly | Not managed by drinking less, which worsens urgency and invites the infections that trigger attacks |
| Vision | Low-vision assessment, contrast and colour measured as well as acuity, and aids and adaptations rather than waiting | Not a promise of recovery. What an attack has taken from the nerve is largely what remains |
| Fatigue and heat | Energy planned rather than improvised, cooling as infrastructure, and the vascular and sleep contributors addressed | Not laziness, and not a reason to rest into deconditioning, which then looks like progression |
| Mood | Treated in its own right, and asked about rather than inferred from the fact that someone has a chronic condition | Not a characterisation of how someone is coping, and not left to be discovered at home |
| Bowel and sexual function | Routine, predictable management, and asked about rather than volunteered | Not an indignity, and among the items with the most available treatments |
The pattern across all seven is the same: the intervention is chosen for the symptom, and it works whether or not the disease is active. Which is precisely why a review built around whether a new lesion has appeared will miss almost all of them, and why a review that lists them as items will not.
What rehabilitation actually does
Rehabilitation here is not a general programme of getting stronger. It is work aimed at the specific deficits a particular attack left, and it is most effective when it starts during or shortly after the attack rather than after a period of waiting to see what recovers.
What it contains, in the order it usually matters: mobility and transfers, including the equipment and the home changes that decide whether someone can get out of a chair and into a bathroom; the management of tone, because spasticity that is treated changes what walking is possible far more than strengthening does; upper-limb function where a cervical lesion has left the hands involved; bladder and bowel programmes rather than advice; and vision rehabilitation, which is a distinct discipline and one that people are rarely referred to.
Two things are worth insisting on. The first is that rehabilitation is re-assessed rather than completed, because what a person needs at three months after an attack is not what they need at twelve. The second is that it is measured — a timed walk, what has been given up, what the bladder does — because a measurement taken now is the only way to know later whether something is changing.
What the months and years afterwards contain
What a person is entitled to after an attack is not a prediction but a plan, and the plan has five parts. Whether the maintenance treatment has been started or reviewed, and which agent with what monitoring. What is measured at each visit and at what interval — the timed walk, the visual acuity and colour, the bladder, the sensory level. Which symptoms are asked about by name rather than left to be volunteered. What would count as a reason to act: a new symptom lasting more than a day, with no fever and no explanation. And how the interval after delivery is handled, where that is relevant, because the postpartum months carry a higher risk of attack.
What should also be said out loud, because families carry it privately, is that the condition is not anyone's fault and does not follow from anything anyone did. What is in a person's hands is not the disease but the interval between attacks — and that is what the prevention page is about.